Tharimmune, Inc. announced on November 13, 2024, that the European Patent Office intends to grant the company a patent. This patent covers biodegradable polymeric nanoparticles designed for carrying therapeutic and targeting agents.
This innovative platform is specifically designed to enhance the delivery of therapeutic antibodies and peptides, which often face limitations due to enzymatic degradation and poor systemic circulation. The technology holds particular utility in cancer therapies.
The granting of this patent strengthens Tharimmune's intellectual property portfolio. It supports the company's strategy to develop novel, targeted biologics and small molecules, creating a competitive advantage through unique therapeutic delivery.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.